CG Oncology reports FY2025 net loss $161M; cash $903M provides runway to 1H 2029

CG Oncology, Inc.

2025-FY EPS reported -$2.08 revenue$4,040,000

Q4 2025 net loss $41.3M ($0.52/share) vs $31.8M ($0.46/share) in Q4 2024.
Full-year 2025 net loss $161.0M ($2.08/share) vs $88.0M ($1.41/share) in FY2024.
Cash, equivalents, and securities ~$903M as of Feb 26, 2026; funded into first half 2029.
PIVOT-006 Phase 3 topline data in intermediate-risk NMIBC expected 1H 2026.
CORE-008 Cohort CX first combination results with gemcitabine in HR NMIBC expected 1H 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.